Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

Related collections

Most cited references 64

Record: found
Abstract: found
Article: not found

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

Freddie Bray, Jian-Song Ren, Eric Masuyer … (2013)

Recent estimates of global cancer incidence and survival were used to update previous figures of limited duration prevalence to the year 2008. The number of patients with cancer diagnosed between 2004 and 2008 who were still alive at the end of 2008 in the adult population is described by world region, country and the human development index. The 5-year global cancer prevalence is estimated to be 28.8 million in 2008. Close to half of the prevalence burden is in areas of very high human development that comprise only one-sixth of the world's population. Breast cancer continues to be the most prevalent cancer in the vast majority of countries globally; cervix cancer is the most prevalent cancer in much of Sub-Saharan Africa and Southern Asia and prostate cancer dominates in North America, Oceania and Northern and Western Europe. Stomach cancer is the most prevalent cancer in Eastern Asia (including China); oral cancer ranks as the most prevalent cancer in Indian men and Kaposi sarcoma has the highest 5-year prevalence among men in 11 countries in Sub-Saharan Africa. The methods used to estimate point prevalence appears to give reasonable results at the global level. The figures highlight the need for long-term care targeted at managing patients with certain very frequently diagnosed cancer forms. To be of greater relevance to cancer planning, the estimation of other time-based measures of global prevalence is warranted. Copyright © 2012 UICC.

0 comments Cited 597 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

Felix Kratz (2008)

Albumin is playing an increasing role as a drug carrier in the clinical setting. Principally, three drug delivery technologies can be distinguished: coupling of low-molecular weight drugs to exogenous or endogenous albumin, conjugation with bioactive proteins and encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in solid tumors forms the rationale for developing albumin-based drug delivery systems for tumor targeting. Clinically, a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clinically. Abraxane has been approved for treating metastatic breast cancer. An alternative strategy is to bind a therapeutic peptide or protein covalently or physically to albumin to enhance its stability and half-life. This approach has been applied to peptides with antinociceptive, antidiabetes, antitumor or antiviral activity: Levemir, a myristic acid derivative of insulin that binds to the fatty acid binding sites of circulating albumin, has been approved for the treatment of diabetes. Furthermore, Albuferon, a fusion protein of albumin and interferon, is currently being assessed in phase III clinical trials for the treatment of hepatitis C and could become an alternative to pegylated interferon. This review gives an account of the different drug delivery systems which make use of albumin as a drug carrier with a focus on those systems that have reached an advanced stage of preclinical evaluation or that have entered clinical trials.

0 comments Cited 453 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals.

Subash C Gupta, Ji Kim, Sahdeo Prasad … (2010)

Almost 25 centuries ago, Hippocrates, the father of medicine, proclaimed "Let food be thy medicine and medicine be thy food." Exploring the association between diet and health continues today. For example, we now know that as many as 35% of all cancers can be prevented by dietary changes. Carcinogenesis is a multistep process involving the transformation, survival, proliferation, invasion, angiogenesis, and metastasis of the tumor and may take up to 30 years. The pathways associated with this process have been linked to chronic inflammation, a major mediator of tumor progression. The human body consists of about 13 trillion cells, almost all of which are turned over within 100 days, indicating that 70,000 cells undergo apoptosis every minute. Thus, apoptosis/cell death is a normal physiological process, and it is rare that a lack of apoptosis kills the patient. Almost 90% of all deaths due to cancer are linked to metastasis of the tumor. How our diet can prevent cancer is the focus of this review. Specifically, we will discuss how nutraceuticals, such as allicin, apigenin, berberine, butein, caffeic acid, capsaicin, catechin gallate, celastrol, curcumin, epigallocatechin gallate, fisetin, flavopiridol, gambogic acid, genistein, plumbagin, quercetin, resveratrol, sanguinarine, silibinin, sulforaphane, taxol, gamma-tocotrienol, and zerumbone, derived from spices, legumes, fruits, nuts, and vegetables, can modulate inflammatory pathways and thus affect the survival, proliferation, invasion, angiogenesis, and metastasis of the tumor. Various cell signaling pathways that are modulated by these agents will also be discussed.

0 comments Cited 210 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Cancers (Basel)

Journal ID (iso-abbrev): Cancers (Basel)

Journal ID (publisher-id): cancers

Title: Cancers

Publisher: MDPI

ISSN (Electronic): 2072-6694

Publication date (Electronic): 01 January 2020

Publication date Collection: January 2020

Volume: 12

Issue: 1

Electronic Location Identifier: 113

Affiliations

[1 ]Department of Pharmaceutical Sciences, Yarmouk University—Faculty of Pharmacy, Irbid 566, Jordan

[2 ]School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, Northern Ireland, UK

[3 ]Department of Mathematics and Sciences, College of Arts and Applied Sciences Dhofar University Salalah, Salalah 211, Oman

[4 ]Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta 31111, Egypt

[5 ]Department of Biological Sciences, Yarmouk University—Faculty of Science, Irbid 566, Jordan

[6 ]Department of Basic Medical Sciences, Yarmouk University—Faculty of Medicine, Irbid 566, Jordan

[7 ]Department of Pharmacy and Biomedical Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK

[8 ]School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India

[9 ]Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow, Klinikum Charite-Universitatmedizin Berlin, augustenburger Platz 1, 13353 Berlin, Germany

[10 ]Department of Dermatology, Venerology, and allergology, Charite—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Chariteplatz1, 10117 Berlin, Germany

[11 ]Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, India

[12 ]School of Pharmacy, Royal College of Surgeons in Ireland, Dublin-09 D02 YN77, Ireland

[13 ]Department of Forensic Science, School of Applied Science, Huddersfield University, Queensgate, Huddersfield HD1 3DH, UK

[14 ]Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India

[15 ]School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India

[16 ]Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 230, Australia

[17 ]Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India

[18 ]Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña McKenna 4860, 7820436, Macul, Santiago 4860, Chile

[19 ]School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, India 173229, India

[20 ]Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia

[21 ]School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK

[22 ]Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, NSW 2007, Australia

[23 ]Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia

Author notes

[* ]Correspondence: m.tambuwala@ 123456ulster.ac.uk ; Tel.: +44-28-701-24016; Fax: +44-28-701-23518

[†]

These authors contributed equally to this study.

Author information

Khalid M. Al-Batanyeh https://orcid.org/0000-0002-3575-2443

Mazhar S. Al Zoubi https://orcid.org/0000-0003-0248-4777

Vijay Mishra https://orcid.org/0000-0001-6542-2464

Deepak N. Kapoor https://orcid.org/0000-0002-3902-7548

Dinesh Kumar Chellappan https://orcid.org/0000-0001-5567-6663

Mateus Webba da Silva https://orcid.org/0000-0002-0825-6276

Kamal Dua https://orcid.org/0000-0002-7507-1159

Murtaza M. Tambuwala https://orcid.org/0000-0001-8499-9891

Article

Publisher ID: cancers-12-00113

DOI: 10.3390/cancers12010113

PMC ID: 7017258

PubMed ID: 31906321

SO-VID: 935d4efc-b81f-4a20-9c52-18be38c9a4a0

License:

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

History

Date received : 12 November 2019

Date accepted : 12 December 2019

Comments

Comment on this article

scite_

Cited by 19

See all cited by

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α

Read this article at

Abstract

Related collections

Nano-Horizons

Most cited references 64

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals.

Author and article information

Journal

Affiliations

Author notes

Author information

Article

History

Categories

Comments

Comment on this article

Similar content 158

Cited by 19